艾坦联合替吉奥在老年晚期胃癌中的疗效及安全性研究

Curative Effect and Safety Research of Apatinini Combined with Tegeol for Elderly Patients with Advanced Gastric Cancer

目的分析艾坦联合替吉奥治疗老年晚期胃癌的效果和不良反应率。方法从2019年9月-2020年9月本院接诊的晚期胃癌老年患者中随机选取140例,使用数字表将所有患者随机均分为对照组(替吉奥)、研究组(替吉奥+阿帕替尼),比较患者的疗效以及不良反应状况。结果研究组治疗有效率明显高于对照组(P<0.05),并且研究组的疾病控制率也明显高于对照组(P<0.05);在治疗过程中的不良反应方面,研究组的发生率显著低于对照组(P<0.05)。结论临床上对老年晚期胃癌患者进行治疗时,较替吉奥的单一治疗而言,替吉奥与阿帕替尼两者的联合治疗,可以明显改善患者的病情,并且用药的安全性更高。

Objective To analyze effect and adverse reaction incidence of apatinini combined with tegeol in treatment of elderly patients with advanced gastric cancer.Methods The paper chose 140 elderly patients with advanced gastric cancer admitted to our hospital from September 2019 to September 2020,and divided them into control group(Tegio)and study group(Tegio+Appatinib)with number table mehtod randomly.Curative effect and adverse reactions of patients was compared.Results Effective rate of treatment in study group was significantly higher than control group(P<0.05),and disease control rate in study group was significantly higher than control group(P<0.05).Incidence of adverse reactions in study group was significantly lower than control group(P<0.05).Conclusion In clinical treatment of elderly patients with advanced gastric cancer,compared with single treatment of tegeol,combination of tegeol and apatinib can improve condition of patients significantly,and drug safety is higher.